Back to Search
Start Over
Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.
- Source :
-
Journal of virology [J Virol] 2020 Jun 16; Vol. 94 (13). Date of Electronic Publication: 2020 Jun 16 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Respiratory syncytial virus (RSV) is the most important cause of lower respiratory tract infection in infants and young children. The vaccine-enhanced disease (VED) has greatly hindered the development of an RSV vaccine. Currently, there are no licensed vaccines for RSV. In this study, immunization of mice with hepatitis B virus core particles containing a conserved region of the G protein (HBc-tG) combined with interleukin-35 (IL-35) elicited a Th1-biased response and a high frequency of regulatory T (Treg) cells and increased the levels of IL-10, transforming growth factor β, and IL-35 production. Importantly, immunization with HBc-tG together with IL-35 protected mice against RSV infection without vaccine-enhanced immunopathology. To explore the mechanism of how IL-35 reduces lung inflammation at the gene expression level, transcription profiles were obtained from lung tissues of immunized mice after RSV infection by the Illumina sequencing technique and further analyzed by a systems biology method. In total, 2,644 differentially expressed genes (DEGs) were identified. Twelve high-influence modules (HIMs) were selected from these DEGs on the basis of the protein-protein interaction network. A detailed analysis of HIM10, involved in the immune response network, revealed that Il10 plays a key role in regulating the host response. The selected DEGs were consistently confirmed by quantitative real-time PCR (qRT-PCR). Our results demonstrate that IL-35 inhibits vaccine-enhanced immunopathology after RSV infection and has potential for development in novel therapeutic and prophylactic strategies. IMPORTANCE In the past few decades, respiratory syncytial virus (RSV) has still been a major health concern worldwide. The vaccine-enhance disease (VED) has hindered RSV vaccine development. A truncated hepatitis B virus core protein vaccine containing the conserved region (amino acids 144 to 204) of the RSV G protein (HBc-tG) had previously been shown to induce effective immune responses and confer protection against RSV infection in mice but to also lead to VED. In this study, we investigated the effect of IL-35 on the host response and immunopathology following RSV infection in vaccinated mice. Our results indicate that HBc-tG together with IL-35 elicited a balanced immune response and protected mice against RSV infection without vaccine-enhanced immunopathology. Applying a systems biology method, we identified Il10 to be the key regulator in reducing the excessive lung inflammation. Our study provides new insight into the function of IL-35 and its regulatory mechanism of VED at the network level.<br /> (Copyright © 2020 American Society for Microbiology.)
- Subjects :
- Animals
Antibodies, Neutralizing immunology
Antibodies, Viral immunology
Cell Line, Tumor
Chlorocebus aethiops
Female
GTP-Binding Proteins immunology
GTP-Binding Proteins metabolism
HEK293 Cells
Hepatitis B virus metabolism
Humans
Immunization
Interleukins metabolism
Lung virology
Mice
Mice, Inbred BALB C
Respiratory Syncytial Virus Infections virology
Respiratory Syncytial Virus Vaccines immunology
Respiratory Syncytial Viruses metabolism
Respiratory Syncytial Viruses pathogenicity
T-Lymphocytes, Regulatory immunology
Th1 Cells immunology
Vaccination
Vero Cells
Viral Core Proteins immunology
Hepatitis B virus immunology
Interleukins immunology
Respiratory Syncytial Virus Infections prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1098-5514
- Volume :
- 94
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Journal of virology
- Publication Type :
- Academic Journal
- Accession number :
- 32321805
- Full Text :
- https://doi.org/10.1128/JVI.00007-20